dazatoN, yes it is it, this kind of a meeting with FDA needs to happen before a new study can start. FDA can give advice and tell to do changes to the study plan. ATH has been planing this ph 2 for a long time, but only now after this meeting, it can start to work according to the plan.
Ann: Meeting with US FDA provides development path for ATH434, page-3
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $6.732K | 2.155M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 17158898 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130236053 | 30 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |